1
|
Jackson RW, Cao-Nasalga A, Chieng A, Pirkl A, Jagielo AD, Xu C, Goldenhersch E, Rosencovich N, Waitman C, Prochaska JJ. Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center's Tobacco Treatment Offerings: Feasibility and Acceptability Single-Group Pilot Study. JMIR Form Res 2024; 8:e54817. [PMID: 39042439 PMCID: PMC11303906 DOI: 10.2196/54817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 04/25/2024] [Accepted: 05/29/2024] [Indexed: 07/24/2024] Open
Abstract
BACKGROUND Smoking contributes to 1 in 3 cancer deaths. At the Stanford Cancer Center, tobacco cessation medication management and counseling are provided as a covered benefit. Patients charted as using tobacco are contacted by a tobacco treatment specialist and offered cessation services. As a novel addition, this study examined the acceptability of a virtual reality (VR) mindful exposure therapy app for quitting smoking called MindCotine. OBJECTIVE The objective of this study was to determine the feasibility and acceptability of offering 6 weeks of MindCotine treatment as a part of Stanford's Tobacco Treatment Services for patients seen for cancer care. METHODS As part of a single-group pilot study, the MindCotine VR program was offered to English- or Spanish-speaking patients interested in quitting smoking. Given the visual interface, epilepsy was a medical exclusion. Viewed from a smartphone with an attachable VR headset, MindCotine provides a digital environment with audiovisual content guiding mindfulness exercises (eg, breathing techniques, body awareness, and thought recognition), text-based coaching, and cognitive behavioral therapy-based self-reflections for quitting smoking. Interested patients providing informed consent were mailed a MindCotine headset and asked to use the app for 10+ minutes a day. At the end of 6 weeks, participants completed a feedback survey. RESULTS Of the 357 patients reached by the tobacco treatment specialist, 62 (17.3%) were ineligible, 190 (53.2%) were not interested in tobacco treatment services, and 78 (21.8%) preferred other tobacco treatment services. Among the 105 eligible and interested in assistance with quitting, 27 (25.7%) were interested in MindCotine, of whom 20 completed the informed consent, 9 used the program, and 8 completed their end-of-treatment survey. Participants using MindCotine completed, on average, 13 (SD 20.2) program activities, 19 (SD 26) journal records, and 11 (SD 12.3) coaching engagements. Of the 9 participants who used MindCotine, 4 (44%) reported some dizziness with app use that resolved and 7 (78%) would recommend MindCotine to a friend. In total, 2 participants quit tobacco (22.2% reporting, 10% overall), 2 others reduced their smoking by 50% or more, and 2 quit for 24 hours and then relapsed. CONCLUSIONS In a feasibility and acceptability pilot study of a novel VR tobacco treatment app offered to patients at a cancer center, 4 of 9 (44%) reporting and 4 of 20 (20%) overall substantially reduced or quit using tobacco after 6 weeks and most would recommend the app to others. Further testing on a larger sample is warranted. TRIAL REGISTRATION ClinicalTrials.gov NCT05220254; https://clinicaltrials.gov/study/NCT05220254.
Collapse
Affiliation(s)
| | - Ann Cao-Nasalga
- Health Education, Engagement and Promotion, Stanford Health Care, Stanford, CA, United States
| | - Amy Chieng
- Stanford Prevention Research Center, Department of Medicine, Stanford University, Palo Alto, CA, United States
| | - Amy Pirkl
- Health Education, Engagement and Promotion, Stanford Health Care, Stanford, CA, United States
| | - Annemarie D Jagielo
- PGSP-Stanford PsyD Consortium, Palo Alto University, Palo Alto, CA, United States
| | - Cindy Xu
- Health Education, Engagement and Promotion, Stanford Health Care, Stanford, CA, United States
| | - Emilio Goldenhersch
- Laboratorio de Investigación en Neurociencia y Ciencias Sociales, Universidad de Flores, Buenos Aires, Argentina
| | - Nicolas Rosencovich
- Escuela de Ingeniería Biomédica, Universidad Nacional de Córdoba, Córdoba, Argentina
| | | | - Judith J Prochaska
- Stanford Prevention Research Center, Department of Medicine, Stanford University, Palo Alto, CA, United States
| |
Collapse
|
2
|
Scholten PR, Stalpers LJA, Bronsema I, van Os RM, Westerveld H, van Lonkhuijzen LRCW. The effectiveness of smoking cessation interventions after cancer diagnosis: A systematic review and meta-analysis. J Cancer Policy 2024; 39:100463. [PMID: 38065242 DOI: 10.1016/j.jcpo.2023.100463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/11/2023] [Accepted: 12/03/2023] [Indexed: 03/08/2024]
Abstract
OBJECTIVES patients with cancer who smoke have more side effects during and after treatment, and a lower survival rate than patients with cancer who quit smoking. Supporting patients with cancer to quit smoking should be standard care. The aim of this systematic review was to determine the most effective smoking cessation method for patients diagnosed with cancer. METHODS PubMed, Embase, Web of Science and Google Scholar were systematically searched. Included were randomized controlled trials and observational studies published after January 2000 with any smoking cessation intervention in patients with any type of cancer. Result of these studies were evaluated in a meta-analysis. RESULTS A total of 18,780 papers were retrieved. After duplicate removal and exclusion based on title and abstract, 72 publications were left. After full text screening, 19 (randomized) controlled trials and 20 observational studies were included. The overall methodological quality of the included studies, rated by GRADE criteria, was very low. Two out of 21 combined intervention trials showed a statistical significant effect. Meta-analysis of 18 RCTs and 3 observational studies showed a significant benefit of combined modality interventions (OR 1.67, 95% C.I.: 1.24-2.26, p = 0.0008) and behavioural interventions (OR 1.33, 95% C.I.: 1.02 - 1.74, p = 0.03), but not for single modality pharmacological interventions (OR 1.11; 95% C.I.: 0.69-1.78, p = 0.66). CONCLUSION A combination of pharmacological and behavioural interventions may be the most effective intervention for smoking cessation in patients with cancer.
Collapse
Affiliation(s)
- Peter R Scholten
- Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Department of Radiotherapy, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
| | - Lukas J A Stalpers
- Department of Radiotherapy, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
| | - Iris Bronsema
- Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Department of Radiotherapy, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
| | - Rob M van Os
- Department of Radiotherapy, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
| | - Henrike Westerveld
- Department of Radiotherapy, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
| | - Luc R C W van Lonkhuijzen
- Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC, University of Amsterdam, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
| |
Collapse
|
3
|
Burnett C, Bestall J, Boland A, Burke S, Callister M, Greenwood-Wilson S, Hewison J, Morgan E, Murray RL, Pompili C, Sloss A, Williams G, Franks K. The Prehabilitation Radiotherapy Exercise, smoking Habit cessation and Balanced diet Study (PREHABS) protocol to explore the feasibility of embedding behavioural modifications into the clinical pathway for patients undergoing radical radiotherapy for lung cancer. BMJ Open 2024; 14:e081365. [PMID: 38272548 PMCID: PMC10824008 DOI: 10.1136/bmjopen-2023-081365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 12/11/2023] [Indexed: 01/27/2024] Open
Abstract
Patients with curable non-surgical lung cancer are often current smokers, have co-existing medical comorbidities and are treated with curative radiotherapy. To maximise the benefits of modern radiotherapy, there is an urgent need to optimise the patient's health to improve survival and quality of life. METHODS AND ANALYSIS The Yorkshire Cancer Research-funded Prehabilitation Radiotherapy Exercise, smoking Habit cessation and Balanced diet Study (PREHABS) (L426) is a single-centre prospective feasibility study to assess embedding behavioural changes into the radical radiotherapy pathway of patients with lung cancer. Feasibility will be assessed by measuring acceptability, demand and implementation. The duration of the study is 24 months. PREHABS has two workstreams: the intervention study and the theory of change (ToC) study.Intervention study: PREHABS will commence at the R-IDEAL phase 2 trial (exploratory) based on existing evidence and includes support for smoking cessation, increasing activity and dietary well-being. Patients undergoing radical radiotherapy for lung cancer will be recruited from the oncology department at Leeds Teaching Hospitals NHS Trust (LTHT). ToC study: to maximise the acceptability and adherence to the PREHABS, we will use a ToC approach to qualitatively explore the key barriers and enablers of implementing a tailored programme of 'prehabilitation'. The PREHABS ToC study participants will be recruited from patients with lung cancer undergoing radical radiotherapy and staff from the LTHT oncology department. ANALYSIS The primary endpoint analysis will report the number of participants and adherence to the study interventions. Secondary endpoints include continued engagement with study interventions post-treatment. The analysis will focus on descriptive statistics. Thematic analysis of the qualitative data from the ToC study will identify consensus on intervention optimisation and delivery. ETHICS AND DISSEMINATION On 12 May 2021, the Cambridge East Ethics Committee granted ethical approval (21/EE/0048). The study is registered in the National Institute for Health and Care Research (NIHR) portfolio. The results will be disseminated through publication in peer-reviewed scientific journals and presented at conferences. TRIAL REGISTRATION NUMBER NIHR portfolio 48420.
Collapse
Affiliation(s)
- Carole Burnett
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- Leeds Institute of Medical Research, University of Leeds, Leeds, UK
| | - Janine Bestall
- Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
| | - Alison Boland
- Leeds Centre for Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, Leeds, UK
| | - Shaunna Burke
- School of Biomedical Sciences, University of Leeds, Leeds, UK
| | - Matthew Callister
- Leeds Centre for Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, Leeds, UK
| | - Samuel Greenwood-Wilson
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- Leeds Institute of Medical Research, University of Leeds, Leeds, UK
| | - Jenny Hewison
- Psychiatry and Behavioural Sciences School of Medicine, University of Leeds, Leeds, UK
| | - Emma Morgan
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Rachael L Murray
- Academic Unit of Lifespan and Population Health, University of Nottingham, Nottingham, UK
| | | | - Andy Sloss
- Patient Representative, Patient Representative, Leeds, UK
| | - Gillian Williams
- Department of Nutrition and Dietetics, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Kevin Franks
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- Faculty of Medicine and Health, University of Leeds, Leeds, UK
| |
Collapse
|
4
|
Halms T, Strasser M, Hasan A, Rüther T, Trepel M, Raab S, Gertzen M. Smoking and quality of life in lung cancer patients: systematic review. BMJ Support Palliat Care 2024; 13:e686-e694. [PMID: 37607808 DOI: 10.1136/spcare-2023-004256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 08/09/2023] [Indexed: 08/24/2023]
Abstract
OBJECTIVES Lung cancer (LC) accounts for the largest number of cancer deaths worldwide, with smoking being the leading cause for its development. While quality of life (QoL) is a crucial factor in the treatment of patients with LC, the impact of smoking status on QoL remains unclear. This systematic review aims to provide a comprehensive overview of available evidence on the relationship between smoking status and QoL among patients with LC. METHODS A systematic search of Embase, Medline and Web of Science was conducted. Studies reporting the impact of smoking status on QoL among patients with LC were eligible for inclusion. Two reviewers independently assessed the eligibility of studies, extracted data and evaluated the risk of bias using the Critical Appraisal Skills Programme appraisal tool for cohort studies. A descriptive synthesis was performed due to the heterogeneity of the studies. RESULTS A total of 23 studies met the inclusion criteria (17 studies providing cross-sectional and 6 longitudinal data). The studies included a total of 10 251 participants. The results suggested a tendency towards lower QoL among smokers compared with non-smokers. The effect of smoking cessation on QoL was insufficiently investigated in the included studies and therefore remains inconclusive. CONCLUSIONS The findings of this review suggest that current smokers may experience worse QoL than former and never smokers. The results of this systematic review should, however, be viewed in the context of the difficulty of data collection in this patient group given the low survival rates and low performance status, among other factors and in light of the large variety of different QoL measures used. Future research requires uniform QoL measures, a holistic representation of all patients with LC as well as a comprehensive consideration of all potential determinants of QoL. The potential benefits of smoking cessation on QoL among patients with LC require investigation.
Collapse
Affiliation(s)
- Theresa Halms
- Department of Psychiatry and Psychotherapy, Medical Faculty, University of Augsburg, Augsburg, Germany
| | - Martina Strasser
- Department of Psychiatry and Psychotherapy, Medical Faculty, University of Augsburg, Augsburg, Germany
| | - Alkomiet Hasan
- Department of Psychiatry and Psychotherapy, Medical Faculty, University of Augsburg, Augsburg, Germany
| | - Tobias Rüther
- Department of Psychiatry and Psychotherapy, University Hospital, Ludwig‑Maximilians University Munich, Munich, Germany
| | - Martin Trepel
- Department of Hematology and Oncology, Medical Faculty, University of Augsburg, University Hospital Augsburg, Augsburg, Germany
- Comprehensive Cancer Center Augsburg (CCCA), Augsburg, Germany
| | - Stephan Raab
- Department of Thoracic Surgery, University Hospital Augsburg, Augsburg, Germany
| | - Marcus Gertzen
- Department of Psychiatry and Psychotherapy, Medical Faculty, University of Augsburg, Augsburg, Germany
| |
Collapse
|
5
|
Feuer Z, Michael J, Morton E, Matulewicz RS, Sheeran P, Shoenbill K, Goldstein A, Sherman S, Bjurlin MA. Systematic review of smoking relapse rates among cancer survivors who quit at the time of cancer diagnosis. Cancer Epidemiol 2022; 80:102237. [PMID: 35988307 PMCID: PMC10363369 DOI: 10.1016/j.canep.2022.102237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 07/30/2022] [Accepted: 08/06/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Tobacco cessation, at the time of cancer diagnosis, has been associated with better oncologic outcomes. Cancer diagnosis has been shown to serves as a "teachable moment," inspiring tobacco cessation. However, the sustainability of abstinence from smoking is understudied. Similarly, there is a paucity of data regarding the utility of behavioral/pharmacologic intervention to support continued smoking cessation. METHODS A systematic literature review was conducted in August 2021 with no date limits. Relevant studies that reported tobacco smoking relapse rates for patients who quit at the time of cancer diagnosis were included. Our literature search identified 1620 articles and 29 met inclusion criteria. The primary endpoint of the study was smoking relapse rate. Secondary outcome was a descriptive assessment of behavioral and pharmacologic interventions to promote continued cessation. Exploratory outcomes included a regression analysis to examine associations between study factors and relapse rates. RESULTS There were 3021 smokers who quit at the time of cancer diagnosis. Weighted overall relapse rate for the study population was 44 % (range 5-57 %). Interventions to support smoking cessation were employed in 17 of the 29 included studies and protocols were heterogenous, including behavioral, pharmacologic, or mixed intervention strategies. Exploratory analysis demonstrated no association between relapse rates and publication year, gender, or study type. Relapse rates were indirectly associated with age (p = .003), suggesting that younger patients were more likely to relapse. CONCLUSION The sustainability of smoking cessation after a cancer diagnosis is understudied, and existing literature is difficult to interpret due to heterogeneity. Relapse rates remain significant and, although many studies have included the employment of an intervention to promote continued cessation, few studies have measured the effect of a protocolized intervention to support abstinence.
Collapse
Affiliation(s)
- Zachary Feuer
- Department of Urology, NYU Langone Health, New York, NY, United States
| | - Jamie Michael
- School of Medicine, University of North Carolina at Chapel Hill, NC, United States
| | - Elizabeth Morton
- Health Sciences Library, University of North Carolina at Chapel Hill, NC, United States
| | - Richard S Matulewicz
- Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | - Paschal Sheeran
- Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, NC, United States; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, United States
| | - Kimberly Shoenbill
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, United States; Department of Family Medicine, University of North Carolina at Chapel Hill, NC, United States; Program on Health and Clinical Informatics, University of North Carolina at Chapel Hill, NC, United States
| | - Adam Goldstein
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, United States; Department of Family Medicine, University of North Carolina at Chapel Hill, NC, United States
| | - Scott Sherman
- Section on Tobacco, Alcohol and Drug Use, Department of Population Health, NYU School of Medicine, New York, NY, United States
| | - Marc A Bjurlin
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, United States; Department of Urology, University of North Carolina at Chapel Hill, NC, United States.
| |
Collapse
|
6
|
Smith J, Woolley T, Brown A, Vangaveti V, Chilkuri M. Smoking cessation in head and neck cancer patients: Factors influencing successes and failures. J Med Imaging Radiat Oncol 2021; 65:233-241. [PMID: 33620161 DOI: 10.1111/1754-9485.13158] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 01/22/2021] [Accepted: 01/26/2021] [Indexed: 02/05/2023]
Abstract
INTRODUCTION This study investigated the smoking behaviours and cessation rates of head and neck cancer (HNC) patients, and their barriers and facilitators to cessation. METHOD The study used a mixed methods, sequential explanatory design. The quantitative data were collected at baseline (around time of cancer diagnosis) via a survey prior to commencement of treatment. Participants identified as current smokers at baseline were then followed up to determine their smoking status after treatment and asked to participate in one-on-one, semi-structured interviews. RESULTS Sixty-four participants with HNC were recruited, with 29 classified as current smokers. The 7-day point prevalence cessation rate for current smokers was 72% at 1-month follow-up, and 67% at 3 months, while continuous smoking cessation was 54% at 1 month, and 42% at 3 months. Participants who continued smoking were found to consume more alcohol (P = 0.032), be in a lower stage of change (pre-contemplation or contemplation stages of the transtheoretical model) at baseline (P = 0.012) and be less confident in being able to cease smoking (P = 0.004). Qualitative analysis revealed 5 key themes associated with smoking cessation: the teachable moment of a cancer diagnosis and treatment, willpower and cessation aids, psychosocial environment, relationship with alcohol and marijuana, and health knowledge and beliefs surrounding smoking and cancer. CONCLUSIONS This study demonstrates that the majority of HNC patients achieve smoking cessation, but relapses are common. Cessation programmes should be developed that are comprehensive, sustained and address factors such as alcohol, marijuana and depression.
Collapse
Affiliation(s)
- Justin Smith
- College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.,Department of Radiation Oncology, Townsville University Hospital, Townsville, Queensland, Australia
| | - Torres Woolley
- College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia
| | - Amy Brown
- Department of Radiation Oncology, Townsville University Hospital, Townsville, Queensland, Australia
| | - Venkat Vangaveti
- College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia
| | - Madhavi Chilkuri
- College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.,Department of Radiation Oncology, Townsville University Hospital, Townsville, Queensland, Australia
| |
Collapse
|
7
|
Phillips JD, Fay KA, Ramkumar N, Hasson RM, Fannin AV, Millington TM, Finley DJ. Long-Term Outcomes of a Preoperative Lung Resection Smoking Cessation Program. J Surg Res 2020; 254:110-117. [PMID: 32428728 PMCID: PMC10750226 DOI: 10.1016/j.jss.2020.04.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 04/07/2020] [Accepted: 04/12/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Smoking cessation programs for patients with cancer suggest 6-mo quit rates between 22% and 40%, and 1-y rates of 33%. We sought to investigate the long-term outcomes of an intensive, preoperative smoking cessation program in patients undergoing lung resection. MATERIAL AND METHODS A retrospective analysis of an IRB-approved, prospective database was performed. Elective lung resections between January 1, 2015 and June 30, 2017 were identified. Demographics, smoking status, pack years, occurrence of smoking cessation counseling, complications, and quit date were obtained. Smoking cessation included face-to-face motivational interviewing, choice of nicotine replacement therapy, discussion that surgery may be canceled or delayed without cessation, and follow-up as needed. RESULTS A total of 340 patients underwent lung resection. Of these, 82 patients were classified as current smokers. All were advised to quit and encouraged to meet with a certified tobacco treatment specialist. Sixty-three patients met with a tobacco treatment specialist and 19 did not. Overall, 60 patients (73%) were able to quit before surgery. At 2 y postoperatively, 15 (18%) were lost to follow-up and 9 (11%) had died. Excluding deaths and censoring those lost to follow-up, cessation rates at 6, 12, and 24 mo postoperatively were 55.3%, 55.6%, and 51.7%, respectively. CONCLUSIONS Implementation of an intensive smoking cessation program in the preoperative period demonstrated high initial, mid-term, and long-term success rates. The preoperative period, particularly one centered around lung cancer, is an effective time for smoking cessation intervention and can lead to a high rate of cessation up to 2 y after surgery.
Collapse
Affiliation(s)
- Joseph D Phillips
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Section of Thoracic Surgery, Lebanon, New Hampshire.
| | - Kayla A Fay
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Section of Thoracic Surgery, Lebanon, New Hampshire
| | - Niveditta Ramkumar
- The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire
| | - Rian M Hasson
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Section of Thoracic Surgery, Lebanon, New Hampshire
| | - Alexandra V Fannin
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Section of Thoracic Surgery, Lebanon, New Hampshire
| | - Timothy M Millington
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Section of Thoracic Surgery, Lebanon, New Hampshire
| | - David J Finley
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Section of Thoracic Surgery, Lebanon, New Hampshire
| |
Collapse
|
8
|
Lucchiari C, Masiero M, Botturi A, Pravettoni G. Helping patients to reduce tobacco consumption in oncology: a narrative review. SPRINGERPLUS 2016; 5:1136. [PMID: 27504234 PMCID: PMC4954805 DOI: 10.1186/s40064-016-2798-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 07/08/2016] [Indexed: 11/10/2022]
Abstract
The present overview focuses on evidence of smoking cessation approaches in oncology settings with the aim to provide health personnel a critical perspective on how to help their patients. This narrative review is structured in two main sections: the first one describes the psycho-cognitive variables involved in the decision to continue smoking after a cancer diagnosis and during the treatment; the second section relates methods and tools may be recommended, being evidence-based, to support smoking cessation in oncology settings. Active smoking increases not only susceptibility to common cancers in the general population, but also increases disease severity and comorbidities in cancer patients. Nowadays, scientific evidence has identified many strategies to give up smoking, but a lack of knowledge exists for treatment of nicotine dependence in the cancer population. Health personnel is often ambiguous when approaching the problem, while their contribution is essential in guiding patients towards healthier choices. We argue that smoking treatments for cancer patients deserve more attention and that clinical features, individual characteristics and needs of the patient should be assessed in order to increase the attempts success rate. Health personnel that daily work and interact with cancer patients and their caregivers have a fundamental role in the promotion of the health changing. For this reason, it is important that they have adequate knowledge and resources in order to support cancer patients to stop tobacco cigarette smoking and promoting and healthier lifestyle.
Collapse
Affiliation(s)
- Claudio Lucchiari
- />Department of Philosophy, Università degli Studi di Milano, Milan, Italy
| | - Marianna Masiero
- />Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
- />Applied Research Unit for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy
| | - Andrea Botturi
- />Department of Neurooncology, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
| | - Gabriella Pravettoni
- />Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
- />Applied Research Unit for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy
| |
Collapse
|
9
|
Follow-up and Survivorship in Head and Neck Cancer. Clin Oncol (R Coll Radiol) 2016; 28:451-8. [DOI: 10.1016/j.clon.2016.03.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Revised: 02/23/2016] [Accepted: 03/03/2016] [Indexed: 12/14/2022]
|
10
|
Gilbert E, Sherry V. Applying Metrics to Outpatient Oncology Advanced Practice Providers. J Adv Pract Oncol 2016; 7:192-202. [PMID: 28090368 PMCID: PMC5226311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
De Zoysa N, Lee A, Joshi A, Guerrero-Urbano T, Lei M, McGurk M, Lyons A, Cascarini L, Jeannon J, Simo R, Ali S, Oakley R. Developing a follow-up surveillance protocol in head and neck oncological surgery: enhanced ‘traffic light’ surveillance - a prospective feasibility study. Clin Otolaryngol 2016; 42:446-450. [DOI: 10.1111/coa.12613] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/13/2015] [Indexed: 11/30/2022]
Affiliation(s)
- N. De Zoysa
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - A. Lee
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - A. Joshi
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | | | - M. Lei
- Department of Clinical Oncology-Guy's & St Thomas; NHS Trust; London UK
| | - M. McGurk
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - A. Lyons
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - L. Cascarini
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - J.P. Jeannon
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - R.S. Simo
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - S. Ali
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| | - R. Oakley
- Department of Head and Neck Surgery-Guys & St Thomas; NHS Trust; London UK
| |
Collapse
|
12
|
Counseling Is Effective for Smoking Cessation in Head and Neck Cancer Patients-A Systematic Review and Meta-Analysis. J Oral Maxillofac Surg 2016; 74:1687-94. [PMID: 26973223 DOI: 10.1016/j.joms.2016.02.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 02/02/2016] [Accepted: 02/07/2016] [Indexed: 11/20/2022]
Abstract
PURPOSE The purpose of this systematic review was to describe the efficacy of smoking cessation counseling and the resulting quit rate in patients with head and neck cancer. MATERIALS AND METHODS A systematic literature search was conducted in the PubMed, Embase, and Cochrane databases. Predictor variables were smoking cessation counseling and smoking cessation interventions. The outcome was smoking cessation. Data collection and quality assessment were performed independently by 2 of the authors. Selected publications were assessed for potential risk of bias, and the level of evidence was evaluated using National Health and Medical Research Council guidelines. Review Manager 5.3 was used to conduct the meta-analysis. RESULTS Eight studies involving 1,239 patients were included (3 randomized controlled trials, 3 cohorts, and 2 case series). Smoking cessation was achieved considerably more often in patients who received smoking cessation counseling compared with those who received usual care. CONCLUSIONS This review shows that counseling supplemented with nicotine replacement therapy increases the possibility for smoking cessation in patients with head and neck cancer.
Collapse
|
13
|
Panwar A, Cheung VWF, Lydiatt WM. Supportive Care and Survivorship Strategies in Management of Squamous Cell Carcinoma of the Head and Neck. Hematol Oncol Clin North Am 2015; 29:1159-68. [DOI: 10.1016/j.hoc.2015.07.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Jiménez-Ruiz CA, Andreas S, Lewis KE, Tonnesen P, van Schayck CP, Hajek P, Tonstad S, Dautzenberg B, Fletcher M, Masefield S, Powell P, Hering T, Nardini S, Tonia T, Gratziou C. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J 2015; 46:61-79. [PMID: 25882805 DOI: 10.1183/09031936.00092614] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Accepted: 12/24/2014] [Indexed: 12/18/2022]
Abstract
Chronic obstructive pulmonary disease (COPD), lung cancer, asthma and pulmonary tuberculosis are common pulmonary diseases that are caused or worsened by tobacco smoking. Growing observational evidence suggests that symptoms and prognosis of these conditions improve upon smoking cessation. Despite increasing numbers of (small) randomised controlled trials suggesting intensive smoking cessation treatments work in people with pulmonary diseases many patients are not given specific advice on the benefits or referred for intensive cessation treatments and, therefore, continue smoking.This is a qualitative review regarding smoking cessation in patients with COPD and other pulmonary disorders, written by a group of European Respiratory Society experts. We describe the epidemiological links between smoking and pulmonary disorders, the evidence for benefits of stopping smoking, how best to assess tobacco dependence and what interventions currently work best to help pulmonary patients quit. Finally, we describe characteristics and management of any "hardcore" smoker who finds it difficult to quit with standard approaches.
Collapse
Affiliation(s)
| | - Stefan Andreas
- Lungenfachklinik Immenhausen and Pneumology, Universitätsmedizin Göttingen, Göttingen, Germany
| | - Keir E Lewis
- Dept of Respiratory Medicine, Prince Philip Hospital and Swansea College of Medicine, Swansea, UK
| | - Philip Tonnesen
- Dept of Sleep Medicine, Glostrup Hospital, Glostrup, Denmark
| | - C P van Schayck
- Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, The Netherlands
| | - Peter Hajek
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Serena Tonstad
- Section for Preventive Cardiology, Oslo University Hospital, Oslo, Norway
| | | | | | | | | | | | - Stefano Nardini
- Pulmonary and TB Unit, Ospedale Civile, Vittorio Veneto, Italy
| | - Thomy Tonia
- Institute of Social and Preventive Medicine, University of Bern, Switzerland
| | - Christina Gratziou
- University Centre for Research and Smoking Cessation, Evgenidio Hospital, Medical School, Athens University, Athens, Greece
| |
Collapse
|
15
|
McPhillips D, Evans R, Ryan D, Daneshvar C, Sarkar SA, Breen D. The role of a nurse specialist in a modern lung-cancer service. ACTA ACUST UNITED AC 2015; 24:S21-7. [DOI: 10.12968/bjon.2015.24.sup4.s21] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
| | - Ruth Evans
- Interventional Pulmonology Nurse Navigator, Department of Pulmonary Medicine, Franklin Square Hospital, Baltimore
| | - Daniel Ryan
- Respiratory Specialist Registrar, Rapid Access Lung Clinic, Galway University Hospitals
| | - Cyrus Daneshvar
- Consultant Respiratory Physician, Department of Respiratory Medicine, Plymouth Hospitals NHS Trust
| | - Saiyad A Sarkar
- Pulmonary and Critical Care Medicine, Department of Pulmonary Medicine, Franklin Square Hospital, Baltimore
| | - David Breen
- Consultant Respiratory Physician, Rapid Access Lung Clinic, Galway University Hospitals
| |
Collapse
|
16
|
Timmermans AJ, Lansaat L, Theunissen EAR, Hamming-Vrieze O, Hilgers FJM, van den Brekel MWM. Predictive factors for pharyngocutaneous fistulization after total laryngectomy. Ann Otol Rhinol Laryngol 2014; 123:153-61. [PMID: 24633941 DOI: 10.1177/0003489414522972] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVES Postoperative complications, especially pharyngocutaneous fistulization (PCF), are more frequent after total laryngectomy (TL) performed for salvage after (chemo)radiotherapy than after primary TL. The aim of this study was to identify the incidence of PCF, predictive factors for PCF, and the relationship of PCF to survival. METHODS We performed a retrospective chart review of 217 consecutive patients treated with TL between 2000 and 2010. Univariate and multivariable analysis with logistic regression was used to identify factors associated with PCF. We used a Kaplan-Meier survival analysis. RESULTS The overall incidence of PCF was 26.3% (57 of 217 cases). The incidence of PCF after primary TL was 17.1% (12 of 70), that after salvage TL was 25.5% (25 of 98), that after TLE for a second primary was 37.5% (9 of 24), and that after TL for a dysfunctional larynx was 44.0% (11 of 25). The predictive factors for PCF were hypopharynx cancer (odds ratio [OR], 3.67; 95% confidence interval [CI], 1.74 to 7.71; P = .001), an albumin level of less than 40 g/L (OR, 2.20; 95% CI, 1.12 to 4.33; P = .022), previous chemoradiotherapy (OR, 3.38; 95% CI, 1.34 to 8.52; P = .010), more-extended pharyngeal resection (P = .001), and pharynx reconstruction (P = .002). The median duration of survival was 30 months (95% CI, 17.5 to 42.5); the 2-year overall survival rate was 54%. The median duration of survival of patients with PCF was 23 months (95% CI, 9.4 to 36.6), and that of those without PCF was 31 months (95% CI, 15.0 to 47.0; P = .421). The 2-year overall survival rate was 48% in patients with PCF and 57% in those without PCF (P = .290). CONCLUSIONS Incidence of PCF after TL is significantly higher in patients with hypopharynx cancer, previous chemoradiotherapy, a low albumin level, more-extended pharyngeal resection, or pharynx reconstruction. The occurrence of PCF does not influence the rate of survival.
Collapse
Affiliation(s)
- Adriana J Timmermans
- Department of Head and Neck Oncology and Surgery, University of Amsterdam, Amsterdam, the Netherlands
| | | | | | | | | | | |
Collapse
|
17
|
Harrell PT, Simmons VN, Correa JB, Padhya TA, Brandon TH. Electronic nicotine delivery systems ("e-cigarettes"): review of safety and smoking cessation efficacy. Otolaryngol Head Neck Surg 2014; 151:381-93. [PMID: 24898072 DOI: 10.1177/0194599814536847] [Citation(s) in RCA: 106] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND OBJECTIVES Cigarette smoking is common among cancer patients and is associated with negative outcomes. Electronic nicotine delivery systems ("e-cigarettes") are rapidly growing in popularity and use, but there is limited information on their safety or effectiveness in helping individuals quit smoking. DATA SOURCES The authors searched PubMed, Web of Science, and additional sources for published empirical data on safety and use of electronic cigarettes as an aid to quit smoking. REVIEW METHODS We conducted a structured search of the current literature up to and including November 2013. RESULTS E-cigarettes currently vary widely in their contents and are sometimes inconsistent with labeling. Compared to tobacco cigarettes, available evidence suggests that e-cigarettes are often substantially lower in toxic content, cytotoxicity, associated adverse effects, and secondhand toxicity exposure. Data on the use of e-cigarettes for quitting smoking are suggestive but ultimately inconclusive. CONCLUSIONS Clinicians are advised to be aware that the use of e-cigarettes, especially among cigarette smokers, is growing rapidly. These devices are unregulated, of unknown safety, and of uncertain benefit in quitting smoking. IMPLICATIONS FOR PRACTICE In the absence of further data or regulation, oncologists are advised to discuss the known and unknown safety and efficacy information on e-cigarettes with interested patients and to encourage patients to first try FDA-approved pharmacotherapies for smoking cessation.
Collapse
Affiliation(s)
- Paul Truman Harrell
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Vani Nath Simmons
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - John Bernard Correa
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Tapan Ashvin Padhya
- Department of Otolaryngology-Head and Neck Surgery, University of South Florida College of Medicine, Tampa, Florida, USA
| | - Thomas Henry Brandon
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| |
Collapse
|
18
|
Shin DW, Park JH, Kim SY, Park EW, Yang HK, Ahn E, Park SM, Lee YJ, Lim MC, Seo HG. Guilt, censure, and concealment of active smoking status among cancer patients and family members after diagnosis: a nationwide study. Psychooncology 2013; 23:585-91. [PMID: 24352765 DOI: 10.1002/pon.3460] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Revised: 11/11/2013] [Accepted: 11/11/2013] [Indexed: 11/07/2022]
Abstract
OBJECTIVES We aimed to identify the prevalence of feelings of guilt, censure, and concealment of smoking status among cancer patients and their family members who continued to smoke after the patient's diagnosis. METHODS Among 990 patient-family member dyads, 45 patients and 173 family members who continued to smoke for at least 1 month after the patients' diagnoses were administered questions examining feelings of guilt, censure, and smoking concealment. RESULTS Most patients who continued to smoke reported experiencing feelings of guilt toward their families (75.6%) and censure from their family members (77.8%), and many concealed their smoking from their family members (44.4%) or healthcare professionals (46.7%). Family members who continued to smoke also reported feelings of guilt with respect to the patient (63.6%) and that the patient was critical of them (68.9%), and many concealed their smoking from the patient (28.5%) or healthcare professionals (9.3%). Patients' feeling of guilt was associated with concealment of smoking from family members (55.9% vs. 10.0%) or health care professionals (55.9% vs. 20.0%). Family members who reported feeling guilty (36.5% vs. 16.3%) or censured (34.5% vs. 16.7%) were more likely to conceal smoking from patients. CONCLUSION Many patients and family members continue to smoke following cancer diagnosis, and the majority of them experience feelings of guilt and censure, which can lead to the concealment of smoking status from families or health care professionals. Feelings of guilt, censure, and concealment of smoking should be considered in the development and implementation of smoking cessation programs for cancer patients and family members.
Collapse
Affiliation(s)
- Dong Wook Shin
- Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Seoul, Korea; Cancer Survivorship Clinic, Seoul National University Cancer Hospital, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Practice of laryngectomy rehabilitation interventions: a perspective from Europe/the Netherlands. Curr Opin Otolaryngol Head Neck Surg 2013; 21:230-8. [PMID: 23572017 DOI: 10.1097/moo.0b013e3283610060] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW Total laryngectomy rehabilitation (TLR) in Europe is not uniform, with quite some differences in approach and infrastructure between various countries. In, for example, the Netherlands, Switzerland, Scandinavia, and more recently also in the UK, head and neck cancer (HNC) treatment and rehabilitation shows a high level of centralization in dedicated HNC centres. In other European countries, the level of centralization is lower, with more patients treated in low-volume hospitals. This article focusses on the situation in the Netherlands and, where applicable, will discuss the regional variations in Europe. RECENT FINDINGS Prosthetic surgical voice restoration (PSVR) presently is the method of choice in Europe, and use of oesophageal and electrolarynx voice has moved to the background. In most European countries (except the UK and Ireland), PSVR is physician driven, with an indispensable role for speech-language pathologists and increasingly for oncology nurses. Indwelling voice prostheses are mostly preferred, also because these devices can be implanted at the time of trachea-oesophageal puncture. Pulmonary rehabilitation is achieved with heat and moisture exchangers, which, based on extensive clinical and basic physiology research, are considered an obligatory therapy measure. In addition to PSVR, also issues such as smoking cessation, dysphagia/swallowing rehabilitation, and olfaction/taste rehabilitation are discussed. Especially, the latter has shown great progress over the last decade and is another example of increasing implementation of evidence-based practice in TLR. SUMMARY TLR has shown considerable progress over the last decades, and through the intensified collaboration between all clinicians involved, significantly has improved vocal, pulmonary, and olfactory rehabilitation after total laryngectomy.
Collapse
|
20
|
Andreas S, Rittmeyer A, Hinterthaner M, Huber RM. Smoking cessation in lung cancer-achievable and effective. DEUTSCHES ARZTEBLATT INTERNATIONAL 2013; 110:719-24. [PMID: 24222790 DOI: 10.3238/arztebl.2013.0719] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Accepted: 08/05/2013] [Indexed: 11/27/2022]
Abstract
BACKGROUND Lung cancer is the leading cause of death from cancer in Germany. 90% of cases are due to the inhalation of tobacco smoke. About 40% of patients with newly diagnosed lung cancer are still smokers. A structured smoking cessation program is medically reasonable in this situation but is only rarely offered. METHODS This review is based on a selective search in the PubMed database combined with a manual search for current publications. RESULTS Many cross-sectional and longitudinal studies have shown that patients with lung cancer benefit from smoking cessation. After resection with curative intent, second tumors are 2.3 times more common, and recurrent tumors 1.9 times more common, in patients who continue to smoke than in those who stop. The overall mortality in smokers is 2.9 times higher. Smoking cessation also lowers the rate of radiation pneumonitis and infection during radiotherapy and prolongs the median survival after chemoradiotherapy for small-cell lung cancer (18.0 vs. 13.6 months). For patients with non-small-cell lung cancer, smoking cessation is associated with a better general state of health (77.5% vs. 57.6%). For the many patients with lung cancer who are treated palliatively, smoking cessation offers the advantages of improved pulmonary function, weight gain, and better overall quality of life. CONCLUSION Smoking cessation in patients with lung cancer is an important means of increasing the efficacy of treatment and improving their quality of life.
Collapse
Affiliation(s)
- Stefan Andreas
- Stefan Andreas and Achim Rittmeyer have equally contributed to the manuscript ; Lung Hospital Immenhausen, pneumological training hospital of Göttingen University
| | | | | | | |
Collapse
|
21
|
Peiffer G, Underner M, Perriot J, Paillot N, Renolleau F. Le sevrage tabagique. REVUE DES MALADIES RESPIRATOIRES ACTUALITÉS 2013. [DOI: 10.1016/s1877-1203(13)70495-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
22
|
Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e61S-e77S. [PMID: 23649454 DOI: 10.1378/chest.12-2349] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Continued tobacco use in the setting of lung cancer management is frequently confounding and always of critical importance. We summarized the published literature concerning the management of tobacco dependence in patients with lung cancer and offer recommendations for integrating dependence treatment into ongoing oncologic care. METHODOLOGY MEDLINE, Embase, CINAHL, PsychINFO, and the Cochrane Collaborative databases were searched for English language randomized clinical trials, cohort studies, case-control studies, secular trend analyses, and case series relevant to the a priori identified clinical questions. Evidence grading, integration, and genesis of recommendations followed the methods described in "Methodology for Development of Guidelines for Lung Cancer" in the American College of Chest Physicians Lung Cancer Guidelines, 3rd ed. RESULTS We describe the approach to tobacco dependence in patients with lung cancer at various phases in the evolution of cancer care. For example, among patients undergoing lung cancer screening procedures, we recommend against relying on the screening itself, including procedures accompanied solely by self-help materials, as an effective strategy for achieving abstinence. Among patients with lung cancer undergoing surgery, intensive perioperative cessation pharmacotherapy is recommended as a method for improving abstinence rates. Cessation pharmacotherapy is also recommended for patients undergoing chemotherapy, with specific recommendations to use bupropion when treating patients with lung cancer with depressive symptoms, as a means of improving abstinence rates, depressive symptoms, and quality of life. CONCLUSIONS Optimal treatment of lung cancer includes attention to continued tobacco use, with abstinence contributing to improved patient-related outcomes at various phases of lung cancer management. Effective therapeutic interventions are available and are feasibly integrated into oncologic care. A number of important clinical questions remain poorly addressed by the existing evidence.
Collapse
Affiliation(s)
- Frank T Leone
- Division of Pulmonary, Allergy, and Critical Care Medicine, Penn Lung Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
| | - Sarah Evers-Casey
- Division of Pulmonary, Allergy, and Critical Care Medicine, Penn Lung Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Benjamin A Toll
- Department of Psychiatry, Yale Comprehensive Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital, New Haven, CT
| | - Anil Vachani
- Division of Pulmonary, Allergy, and Critical Care Medicine, Penn Lung Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
23
|
Kashigar A, Habbous S, Eng L, Irish B, Bissada E, Irish J, Brown D, Gilbert R, Gullane P, Xu W, Huang SH, Witterick I, Freeman J, O'Sullivan B, Waldron J, Liu G, Goldstein D. Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. Cancer 2013; 119:2701-9. [DOI: 10.1002/cncr.28088] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Revised: 02/24/2013] [Accepted: 02/25/2013] [Indexed: 11/11/2022]
Affiliation(s)
- Aidin Kashigar
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
| | - Steven Habbous
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
- Biostatistics; Ontario Cancer Institute; Toronto Ontario Canada
| | - Lawson Eng
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Brendan Irish
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Eric Bissada
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Jonathan Irish
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Dale Brown
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Ralph Gilbert
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Patrick Gullane
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| | - Wei Xu
- Biostatistics; Ontario Cancer Institute; Toronto Ontario Canada
| | - Shao-Hui Huang
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
- Radiation Oncology; University of Toronto; Toronto Ontario Canada
| | - Ian Witterick
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Mt. Sinai Hospital, University Health Network; Toronto Ontario Canada
| | - Jeremy Freeman
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Mt. Sinai Hospital, University Health Network; Toronto Ontario Canada
| | - Brian O'Sullivan
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
- Radiation Oncology; University of Toronto; Toronto Ontario Canada
| | - John Waldron
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
- Radiation Oncology; University of Toronto; Toronto Ontario Canada
| | - Geoffrey Liu
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
- Medicine and Epidemiology; Dalla Lana School of Public Health, University of Toronto; Toronto Ontario Canada
| | - David Goldstein
- Otolaryngology-Head & Neck Surgery; University of Toronto; Toronto Ontario Canada
- Ontario Cancer Institute; Princess Margaret Cancer Centre; Toronto Ontario Canada
| |
Collapse
|
24
|
Shin DW, Cho B, Kim SY, Jung JH, Park JH. Management of cancer survivors in clinical and public health perspectives: current status and future challenges in Korea. J Korean Med Sci 2013; 28:651-7. [PMID: 23678254 PMCID: PMC3653075 DOI: 10.3346/jkms.2013.28.5.651] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2012] [Accepted: 03/04/2013] [Indexed: 12/31/2022] Open
Abstract
The number of cancer survivors is increasing dramatically. Many cancer survivors face lifetime risks associated with their cancer therapy, with a significant proportion at risk for serious morbidity and premature mortality. Concerns regarding the long-term physical, psychosocial, and economic effects of cancer treatment on cancer survivors and their families are increasingly being recognized and addressed by public and private sector. This article summarizes economic burden of cancer survivors, main post-treatment health problems including secondary primary cancer and comorbidities, health behaviors such as smoking, exercise and physical activity, nutrition, and psychosocial problems. Faced with various health and psychosocial problems specific to this population, several healthcare and policy models are being suggested to address these issues, including 'shared care model' and 'integrative supportive care service delivery system for cancer survivors'. More effort is needed to make the cancer survivorship agenda a reality, attended by a wide variety of stakeholders including researchers, patients, providers, and policy makers.
Collapse
Affiliation(s)
- Dong Wook Shin
- Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Seoul, Korea
- Cancer Survivorship Clinic, Seoul National University Cancer Hospital, Seoul, Korea
| | - BeLong Cho
- Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Seoul, Korea
- Cancer Survivorship Clinic, Seoul National University Cancer Hospital, Seoul, Korea
| | - So Young Kim
- Cancer Policy Branch, National Cancer Control Research Institute, National Cancer Center, Goyang, Korea
| | - Je Hyuck Jung
- Division of Disease Policy, Ministry of Health and Welfare, Seoul, Korea
| | - Jong Hyock Park
- Cancer Policy Branch, National Cancer Control Research Institute, National Cancer Center, Goyang, Korea
| |
Collapse
|
25
|
Carson KV, Usmani ZA, Robertson TA, Mysore S, Brinn MP. Smoking cessation interventions for lung cancer patients. Lung Cancer Manag 2013. [DOI: 10.2217/lmt.12.55] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
SUMMARY Worldwide, lung cancer contributes to over 1.4 million deaths per year. Smoking cessation is strongly recommended in clinical practice guidelines for lung cancer management, yet evidence suggests a translational gap between evidence and practice. There are significant health benefits following smoking cessation even after a short period of time. Long-term implications for lung cancer patients include improvements in quality of life, reductions in postoperative complications and reductions in 12-month mortality. Evidence suggests that combining pharmacotherapy, in particular varenicline tartrate (varenicline), with cognitive and behavioral interventions offers the best opportunity for successful long-term abstinence. This review summarizes the latest evidence for smoking cessation interventions in lung cancer patients, identifies gaps in current clinical practice and highlights priority areas for future research.
Collapse
Affiliation(s)
- Kristin V Carson
- The Clinical Practice Unit, The Basil Hetzel Institute for Translational Health Research, Adelaide, Australia
| | - Zafar A Usmani
- Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, Australia
| | - Thomas A Robertson
- Therapeutics Research Centre, School of Pharmacy & Biomedical Sciences, University of South Australia & The Basil Hetzel Institute for Translational Health Research, Adelaide, Australia
| | - Satya Mysore
- Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, Australia
| | - Malcolm P Brinn
- The Clinical Practice Unit, The Basil Hetzel Institute for Translational Health Research, Adelaide, Australia
- Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, Australia
| |
Collapse
|
26
|
Cooley ME, Wang Q, Johnson BE, Catalano P, Haddad RI, Bueno R, Emmons KM. Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer 2012; 76:144-9. [PMID: 22093155 PMCID: PMC3322288 DOI: 10.1016/j.lungcan.2011.10.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2011] [Revised: 10/12/2011] [Accepted: 10/13/2011] [Indexed: 10/15/2022]
Abstract
INTRODUCTION Smoking cessation among cancer patients is critical for improving outcomes. Understanding factors associated with smoking abstinence after the diagnosis of cancer can provide direction to develop and test interventions to enhance cessation rates. The purpose of this study was to identify determinants of smoking outcomes among cancer patients. METHODS Standardized questionnaires were used to collect data from 163 smokers or recent-quitters (quit≤6 months) at study entry of which 132 and 121 had data collected at 3 and 6 months. Biochemical verification was conducted with urinary cotinine and carbon monoxide. Descriptive statistics, Cronbach alpha coefficients, Pearson correlations, Fisher's exact test, and multivariable logistic regression were used for analyses. RESULTS Seven-day-point-prevalence-abstinence (PPA) rates were 90/132 (68%) at 3 months; 46/71 (65%) among lung and 44/61 (72%) among head and neck cancer patients, whereas 7-day-PPA rates were 74/121 (61%) at 6 months; 31/58 (53%) among lung and 43/63 (68%) among head and neck cancer patients. Continuous abstinence rates were 63/89 (71%) at 3 months; 32/45 (71%) among lung and 31/44 (70%) among head and neck cancer patients, whereas continuous abstinence rates were 46/89 (52%) at 6 months; 18/45 (40%) among lung and 28/44 (64%) among head and neck cancer patients. Lower cancer-related, psychological and nicotine withdrawal symptoms were associated with increased 7-D-PPA abstinence rates at 3 and 6 months in univariate models. In multivariable models, however, decreased craving was significantly related with 7-day-PPA at 3 months and decreased craving and increased self-efficacy were associated with 7-D-PPA at 6 months. Decreased craving was the only factor associated with continuous abstinence at 6 months. CONCLUSIONS Smoking outcomes among lung and head and neck cancer patients appear to have remained the same over the last two decades despite the availability of an increased number of pharmacotherapy options to treat tobacco dependence. Decreased craving and increased self-efficacy were the most consistent factors associated with improved smoking outcomes but symptom control may also play a role in optimal management. Use of combined, and/or higher doses of pharmacotherapy along with behavioral interventions that increase self-efficacy and manage symptoms may promote enhanced cessation rates.
Collapse
Affiliation(s)
- Mary E Cooley
- Dana Farber Cancer Institute, Boston, MA 02115, USA. mary
| | | | | | | | | | | | | |
Collapse
|